Alexander Chang
Papers
1
Total Citations
2
H-Index
1
About
Dr. Alexander Chang is a leading clinical researcher in thoracic oncology, with a focused expertise in the treatment of locally advanced non-small cell lung cancer (NSCLC). His major contributions center on the transformative application of neoadjuvant chemoimmunotherapy, where he has helped translate promising clinical trial findings into real-world practice. In his highly cited 2025 study, "Outcomes of Resectable Locally Advanced Non-Small Cell Lung Cancer After Neoadjuvant Chemoimmunotherapy," Dr. Chang demonstrated that combining immunotherapy with chemotherapy before surgery yields a significantly higher rate of pathologic complete response compared to traditional chemotherapy alone. This work, which has already garnered early citations, provides critical evidence for the efficacy of this approach outside of controlled trial settings, offering a blueprint for community and academic oncologists. Dr. Chang’s research is pivotal in reshaping surgical strategies for NSCLC, aiming to improve long-term survival and reduce recurrence. His ongoing work continues to refine patient selection and optimize treatment sequencing, marking him as a key voice in the evolution of lung cancer care.
Research Focus
Key Achievements
Top Papers
- 1